Navigation Links
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
Date:9/22/2010

40 mcg/day

60 mcg/day

80 mcg/dayMean baseline HbA1c (%)

7.96

7.79

8.05

8.03Mean week 24 HbA1c (%)

7.07

6.93

6.67

6.67Mean HbA1c change at week 24

-0.89

-0.86

-1.38

-1.36HbA1c  < 7% at week 24

60%

71%

73%

79%Mean weight change at week 24 (lbs)

-1.8

-7.9

-6.8

-7.7"The reductions in HbA1c and weight are substantial, especially for a group of patients on metformin-only background therapy with baseline HbA1c levels at 8.0 percent.  We look forward to evaluating optimized dose regimens of ITCA 650 in broader patient populations in the phase 3 program," Graves said.

ITCA 650 therapy in the phase 2 trial was administered for the 90-day treatment period with a single insertion of ITCA 650 on day 1 and removal on or around day 90. The extension phase of the 2 trial evaluated higher doses of ITCA 650 using a single device to deliver 3 months of treatment. The phase 3 study planned for early 2011 will evaluate treatment regimens involving initial 12-week ITCA 650 dosing at 20 mcg/day transitioning to 60 mcg/day thereafter using even longer duration ITCA 650 devices.

A downloadable version of the ITCA 650 phase 2 presentation from EASD is available on the Intarcia corporate website at: http://www.intarcia.com/media_presentations.html

About ITCA 650ITCA 650 therapy for type 2 diabetes consists of DUROS continuous subcutaneous delivery of exenatide. The DUROS delivery technology comprises the DUROS device, a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy. Intarcia's proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time.

The DUROS technology can
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Tasly Pharmaceuticals, Inc., the world,s leader ... today the launch of Deepure. Deepure ... men and women concerned with supporting their overall ... age while helping keep their health care cost ... herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and ...
(Date:9/30/2014)... 30, 2014 Aileron Therapeutics, Inc. - ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - Product ... the Aileron Therapeutics, Inc.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Aileron Therapeutics, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... 2014 According to ... by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments ... Application (Immunology, Oncology) & by End User ... MarketsandMarkets, provides a detailed overview of the ... trends, and strategies impacting the global glycomics ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... 9 Peptimmune, Inc., a privately,held biotechnology ... peptide copolymer program at both the 17th ... FOCIS 2008 in Boston, MA. The Company ... study involving,healthy, male adult volunteers following SC ...
... juice has ... NEW YORK, June 9 CherryPharm -- a proprietary,all-natural ... of,cherries -- has been shown to improve aspects of sleep, ... This double-blind,placebo controlled clinical trial tested the effectiveness of CherryPharm,in ...
Cached Medicine Technology:Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings 2Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings 3CherryPharm First All-Natural Food to Improve Sleep 2
(Date:10/2/2014)... -- Genes may interact with stress to trigger heart disease ... risk occurs in about 13 percent of people, but only ... people reduce their heart disease risk through simple measures such ... Duke University researchers said. The study authors analyzed genetic ... between variations in the EBF1 gene and higher levels of ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... roses -- literally -- may face an increased risk of dying ... study of over 3,000 older Americans, researchers found those who were ... more than three times as likely to die in the next ... In fact, anosmia -- the inability to distinguish odors -- was ...
(Date:10/1/2014)... developed a model that could help to predict a ... from their very first psychotic episode. , The model ... symptoms, cognitive abilities, MRI scans of the brain,s structure, ... the lead up to World Mental Health Day (10 ... Professor Bernhard Baune , says the model is a ...
(Date:10/1/2014)... the human eye, the brain of a rat and ... technology, says a QUT leading robotics researcher. , ... says the new study uses new computer algorithms to ... or tunnels. , "This is a very Frankenstein type ... halves of a thing together because we,re taking the ...
(Date:10/1/2014)... encourages people to keep their "eyes on the prize" ... When walking, staying focused on a specific target ahead ... help people walk there faster, psychology researchers have found. ... looking around the environment naturally, offers a new strategy ... less interested in exercise if physical activity seems daunting, ...
Breaking Medicine News(10 mins):Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Predicting the future course of psychotic illness 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... suffered cardiac death would have their bodies prepared for ... Australian Health Ethics Committee that is working on organ ... patients who are certain to die after experiencing cardiac ... heart, liver lungs and kidneys begin to deteriorate immediately ...
... help Alzheimer's patients interact and communicate with others, finds ... Newcastle General Hospital studied the benefits of dolls after ... from her son, reported the online edition of BBC ... can lose their intellectual, social and emotional abilities over ...
... major public health threat posed by antibiotic-resistant bacteria, ... (UCSD) are launching a new program to develop ... and testing, to clinical trials. ,"UCSD ... necessary expertise to fight this urgent medical problem," ...
... discovered around 1994 which has the ability to perform multi ... other crucial physiological activities. , But the ... out these metabolic activities were not known till date. Now, ... University have identifies the mode in which Leptin carries out ...
... University, Doug Goodin, makes use of satellite imagery to ... //changes on human health and food security. ... types of data, to monitor and predict the spread ... discussed this subject at the workshop, "Contributions of Remote ...
... men for a good 14 years has revealed that regular ... body weight has an impact in cutting down the risks ... co-author of the study, said "Even though erectile problems were ... clear that heart disease and ED share many of the ...
Cached Medicine News:Health News:New UCSD Program to Fight Drug-Resistant Bacteria 2Health News:New UCSD Program to Fight Drug-Resistant Bacteria 3Health News:New UCSD Program to Fight Drug-Resistant Bacteria 4Health News:How Does Leptin Work? 2Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2
... Disease ELISA kits utilize ... Also included in each ... negative controls, serum diluent, ... Use an ELISA plate ...
... (PCR) technology, the worlds leading nucleic acid ... Roches blood screening assays and other diagnostic ... unique regions of genetic material to be ... to detectable levels) in only a few ...
... Continuing to lead the market in ... WAVE IABP is a whole new first ... optic technology coupled with a physiologically based ... support with unprecedented timing accuracy. Second ...
... worlds first truly automated immunohistochemistry ... a whole new level of ... modularity and ease of operation ... NexES Systems automated technology provides ...
Medicine Products: